Trials / Recruiting
RecruitingNCT07106762
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
- Status
- Recruiting
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 470 (estimated)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Iza-bren | Specified dose on specified days |
| DRUG | Cisplatin | Specified dose on specified days |
| DRUG | Gemcitabine | Specified dose on specified days |
| DRUG | Carboplatin | Specified dose on specified days |
Timeline
- Start date
- 2025-09-30
- Primary completion
- 2029-01-26
- Completion
- 2033-11-18
- First posted
- 2025-08-06
- Last updated
- 2026-04-15
Locations
160 sites across 22 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, France, Germany, Ireland, Israel, Italy, Japan, Netherlands, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07106762. Inclusion in this directory is not an endorsement.